Myriad unit study shows ‘significant improvement’ in depression outcomes

Assurex Health, a wholly-owned subsidiary of Myriad Genetics, announced that results from a large, well-controlled pharmacogenomics study in patients with major depressive disorder, or MDD, were presented at the American Psychiatric Association annual meeting in New York City. The key finding is that patients were 50% more likely to achieve remission and 30% more likely to respond to treatment when their medication selection was guided by the GeneSight Psychotropic genetic test. “We now have the results from the largest-ever pharmacogenomics clinical study in patients with moderate-to-very severe depression,” said Bryan Dechairo, Ph.D., executive VP of clinical development, Myriad Genetics. “The important news here is that when doctors used the GeneSight genetic test to guide their selection of antidepressants, patients experienced significantly higher rates of response and remission as well as better overall symptom relief.”

https://bit.ly/2HY7n60